GRP
SMMT icon

Global Retirement Partners’s Summit Therapeutics SMMT Stock Holding History

Global Retirement Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.99K Buy
+686
New +$12.2K ﹤0.01% 3400
2024
Q4 		– Sell
-500
Closed -$10.9K – 3770
2024
Q3 		$10.9K Buy
+500
New +$6.99K ﹤0.01% 2264

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Global Retirement Partners's SMMT Position: Q2 2026 in Review

Global Retirement Partners opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 686 shares worth $9.99K. The stake represents ﹤0.01% of the portfolio and ranks #3400 among its holdings. This is a return to the name: Global Retirement Partners previously reported a position in SMMT as recently as Q3 2024.

Global Retirement Partners first reported a position in SMMT in Q3 2024 and has held it in 2 quarters since. The position peaked at $10.9K in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Global Retirement Partners held 686 shares of Summit Therapeutics worth $9.99K as of Q2 2026.
  • Summit Therapeutics was a new Global Retirement Partners position in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Global Retirement Partners's portfolio in Q2 2026, its #3400 holding.
  • Global Retirement Partners first reported a position in Summit Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • Global Retirement Partners's Summit Therapeutics position peaked at $10.9K in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Global Retirement Partners's 13F filing for Q2 2026, filed 6 Aug 2026.